0.3192
price down icon5.95%   -0.0202
after-market Handel nachbörslich: .32 0.0008 +0.25%
loading
Schlusskurs vom Vortag:
$0.3394
Offen:
$0.34
24-Stunden-Volumen:
708.31K
Relative Volume:
0.67
Marktkapitalisierung:
$3.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.74M
KGV:
-0.4929
EPS:
-0.6476
Netto-Cashflow:
$-3.46M
1W Leistung:
-22.67%
1M Leistung:
-23.98%
6M Leistung:
-57.10%
1J Leistung:
-71.24%
1-Tages-Spanne:
Value
$0.302
$0.3499
1-Wochen-Bereich:
Value
$0.302
$0.42
52-Wochen-Spanne:
Value
$0.302
$1.50

Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile

Name
Firmenname
Lipella Pharmaceuticals Inc
Name
Telefon
412-901-0315
Name
Adresse
400 N LEXINGTON ST, PITTSBURGH
Name
Mitarbeiter
7
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
LIPO's Discussions on Twitter

Lipella Pharmaceuticals Inc Aktie (LIPO) Neueste Nachrichten

pulisher
Nov 01, 2024

Lipella Pharmaceuticals Launching 1-for-8 Reverse Stock Split - Marketscreener.com

Nov 01, 2024
pulisher
Nov 01, 2024

Lipella Pharmaceuticals announces 1-for-8 reverse stock split - MSN

Nov 01, 2024
pulisher
Nov 01, 2024

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - GlobeNewswire

Nov 01, 2024
pulisher
Oct 29, 2024

Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference - GlobeNewswire

Oct 29, 2024
pulisher
Oct 19, 2024

Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com India

Oct 19, 2024
pulisher
Oct 18, 2024

Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com South Africa

Oct 18, 2024
pulisher
Oct 18, 2024

Biotech Alert: Searches spiking for these stocks today - TipRanks

Oct 18, 2024
pulisher
Oct 16, 2024

Ocugen Inc (OCGN) rating initates by Maxim Group - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Potential Price Increase for First Advantage Corp. (FA) After Recent Insider Activity - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Lipella Pharmaceuticals Inc (LIPO) Becoming More Attractive for Investors - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Recent Insider Activity Suggests Potential Gains for KE Holdings Inc ADR (BEKE) - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Lipella Pharmaceuticals Inc [LIPO] is -57.84% lower this YTD. Is it still time to buy? - The DBT News

Oct 16, 2024
pulisher
Oct 15, 2024

Allovir (ALVR) Stock Experiences Significant Decline Amid Negati - GuruFocus.com

Oct 15, 2024
pulisher
Oct 15, 2024

Huge semiconductor deal has eyes on this tech co 👀 - RagingBull

Oct 15, 2024
pulisher
Oct 15, 2024

Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform - GlobeNewswire

Oct 15, 2024
pulisher
Oct 13, 2024

Interstitial Cystitis Market Size is Set for Rapid Growth as - openPR

Oct 13, 2024
pulisher
Oct 09, 2024

Sky Quarry Announces Closing of Public Offering of $6.7 Million - The Manila Times

Oct 09, 2024
pulisher
Oct 09, 2024

TSX 60 Shariah Index (TXSI) QuotePress Release - The Globe and Mail

Oct 09, 2024
pulisher
Oct 09, 2024

Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit - GlobeNewswire

Oct 09, 2024
pulisher
Sep 30, 2024

Expion360 Inc’s latest rating changes from various analysts - Knox Daily

Sep 30, 2024
pulisher
Sep 26, 2024

Insider Buying: Kaufman Jonathan H, Lipella Pharmaceuticals Inc [LIPO] insider invested 10,000 shares - Knox Daily

Sep 26, 2024
pulisher
Sep 26, 2024

The time has not yet come to remove your chips from the table: Lipella Pharmaceuticals Inc (LIPO) - SETE News

Sep 26, 2024
pulisher
Sep 25, 2024

Lipella Pharmaceuticals Inc Inc. (LIPO) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

Sep 25, 2024
pulisher
Sep 25, 2024

PRISM MarketView Features Q&A with Dr. Michael Chancellor: - GlobeNewswire

Sep 25, 2024
pulisher
Sep 25, 2024

PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month - Morningstar

Sep 25, 2024
pulisher
Sep 24, 2024

Lipella reports positive phase 2a trial results for OLP treatment - Investing.com

Sep 24, 2024
pulisher
Sep 24, 2024

Lipella Pharmaceuticals Reports Encouraging Early - GlobeNewswire

Sep 24, 2024
pulisher
Sep 24, 2024

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus - StockTitan

Sep 24, 2024
pulisher
Sep 23, 2024

A year in review: Lipella Pharmaceuticals Inc (LIPO)’s performance in the last year - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Lipella Pharmaceuticals Inc’s Market Journey: Closing Weak at 0.41, Down -2.35 - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Lipella stock soars 200% on Phase 2 study initiation - MSN

Sep 23, 2024
pulisher
Sep 19, 2024

Matthew E Korenberg At Ligand Pharmaceuticals Executes Options Exercise, Realizing $260K - Benzinga

Sep 19, 2024
pulisher
Sep 19, 2024

Pliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading Volume - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

John Deneen Collins Sells 85,126 Shares of LivePerson, Inc. (NASDAQ:LPSN) Stock - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

Lepidico Wins Crucial Road Access Dispute - TipRanks

Sep 18, 2024
pulisher
Sep 18, 2024

Louisiana-Pacific director sells $245,750 in company stock By Investing.com - Investing.com Canada

Sep 18, 2024
pulisher
Sep 17, 2024

LivePerson CFO and COO sells over $89k in company stock - Investing.com

Sep 17, 2024
pulisher
Sep 17, 2024

Pliant Therapeutics (NASDAQ:PLRX) Sees Large Volume Increase - MarketBeat

Sep 17, 2024
pulisher
Sep 17, 2024

A stock that deserves closer examination: Lipella Pharmaceuticals Inc (LIPO) - US Post News

Sep 17, 2024
pulisher
Sep 17, 2024

Moody’s to withdraw Lippo Malls Indonesia Retail Trust’s credit ratings - The Edge Singapore

Sep 17, 2024
pulisher
Sep 16, 2024

UK Government gets behind Lepidico’s process technologies - Mining.com.au

Sep 16, 2024
pulisher
Sep 16, 2024

Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $12.00 - MarketBeat

Sep 16, 2024
pulisher
Sep 16, 2024

Understanding the Risks of Investing in Lipella Pharmaceuticals Inc (LIPO) - Knox Daily

Sep 16, 2024
pulisher
Sep 16, 2024

Stock Surge: Lipella Pharmaceuticals Inc (LIPO) Closes at 0.40, Marking a 6.96 Increase/Decrease - The Dwinnex

Sep 16, 2024
pulisher
Sep 13, 2024

A closer look at LIPO’s price-to-free cash flow ratio - US Post News

Sep 13, 2024
pulisher
Sep 12, 2024

Interstitial Cystitis Market Growth Anticipated by 2032 | Companies includes Merck, Teva Pharmaceutical, Lipella Pharmaceuticals, Seikagaku Corporation - Barchart

Sep 12, 2024
pulisher
Sep 12, 2024

Lipella Pharmaceuticals announces board election and reverse stock split - Investing.com

Sep 12, 2024
pulisher
Sep 11, 2024

Lipella Pharmaceuticals Inc [LIPO] Investment Guide: What You Need to Know - Knox Daily

Sep 11, 2024
pulisher
Sep 10, 2024

Lipella Pharmaceuticals stock more than doubles in 3 days as FDA approves IND for OLP treatment - MSN

Sep 10, 2024
pulisher
Sep 09, 2024

A Guide To The Risks Of Investing In Lipella Pharmaceuticals Inc (LIPO) - Knox Daily

Sep 09, 2024
pulisher
Sep 09, 2024

LIPO’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

Sep 09, 2024

Finanzdaten der Lipella Pharmaceuticals Inc-Aktie (LIPO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):